This newsletter presents you the following key sessions:
1. PODCAST with Prof. Michael Gnant about adjuvant palbociclib in HR+/HER2- early breast cancer -
the final results from the PALLAS trial
2. Metformin does not improve breast cancer outcomes in moderate- to high-risk breast cancer
3. Clinical utility of genomic profiling in patients with metastatic breast cancer
4. Entinostat in combination with exemestane is effective in patients with HR+/HER2- advanced breast cancer
5. Elacestrant improves outcomes in patients with ER+/HER2- metastatic breast cancer progressing on prior
endocrine therapy
